WO2012059112A1 - Développement de produits médicaux fondés sur une fonction nouvellement découverte des érythrocytes - Google Patents
Développement de produits médicaux fondés sur une fonction nouvellement découverte des érythrocytes Download PDFInfo
- Publication number
- WO2012059112A1 WO2012059112A1 PCT/EG2010/000041 EG2010000041W WO2012059112A1 WO 2012059112 A1 WO2012059112 A1 WO 2012059112A1 EG 2010000041 W EG2010000041 W EG 2010000041W WO 2012059112 A1 WO2012059112 A1 WO 2012059112A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigens
- rbcs
- transported
- store
- those
- Prior art date
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 75
- 238000011161 development Methods 0.000 title description 3
- 229940127554 medical product Drugs 0.000 title description 2
- 239000000427 antigen Substances 0.000 claims abstract description 131
- 108091007433 antigens Proteins 0.000 claims abstract description 131
- 102000036639 antigens Human genes 0.000 claims abstract description 131
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 210000004369 blood Anatomy 0.000 claims abstract description 18
- 239000008280 blood Substances 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 244000005700 microbiome Species 0.000 claims abstract description 15
- 241001465754 Metazoa Species 0.000 claims abstract description 13
- 229960005486 vaccine Drugs 0.000 claims abstract description 11
- 108010026552 Proteome Proteins 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 4
- 244000045947 parasite Species 0.000 claims abstract 3
- 241000238631 Hexapoda Species 0.000 claims abstract 2
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 238000002255 vaccination Methods 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 201000008680 babesiosis Diseases 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 210000003936 merozoite Anatomy 0.000 claims 2
- 210000003046 sporozoite Anatomy 0.000 claims 2
- 241000223836 Babesia Species 0.000 claims 1
- 241000224016 Plasmodium Species 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000001563 schizont Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- 238000003745 diagnosis Methods 0.000 abstract description 10
- 210000000987 immune system Anatomy 0.000 abstract description 10
- 210000000056 organ Anatomy 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 6
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 5
- 210000003754 fetus Anatomy 0.000 abstract description 5
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 4
- 208000026935 allergic disease Diseases 0.000 abstract description 4
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 230000009610 hypersensitivity Effects 0.000 abstract description 4
- 238000012544 monitoring process Methods 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 206010064912 Malignant transformation Diseases 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 3
- 230000036212 malign transformation Effects 0.000 abstract description 3
- 238000002054 transplantation Methods 0.000 abstract description 3
- 206010052779 Transplant rejections Diseases 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000003319 supportive effect Effects 0.000 abstract description 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 230000032258 transport Effects 0.000 description 7
- 230000004520 agglutination Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 4
- 238000007418 data mining Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241001494479 Pecora Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000000521 hyperimmunizing effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 1
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 208000005469 Vivax Malaria Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000036260 idiopathic disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000003114 pinocytic effect Effects 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- mice • A number of white mice were slaughtered to collect their blood on sodium citrate and their organs (liver, kidney and spleen) were preserved on 10 % formalin.
- RBCs hemolysate was prepared from TB patients showing positive TB smear and from cured TB patients.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention est fondée sur une fonction nouvellement découverte des érythrocytes (globules rouges - GR). On a découvert que les GR contiennent des antigènes qui sont différents de leur protéome. Ces antigènes peuvent être précipités/séparés en utilisant du plasma sanguin dont les GR ont été prélevés. On a trouvé que ces antigènes consistent en des antigènes HLA, en des antigènes spécifiques à un tissu et en des antigènes étrangers. Les antigènes étrangers peuvent être des antigènes de fœtus chez des femelles enceintes, des antigènes tumoraux, des antigènes de microorganismes, des antigènes d'aliments, d'insectes ou d'autres antigènes provenant de l'environnement. L'ensemble de ces antigènes transportés représente une réserve dynamique. Par conséquent, les GR peuvent jouer un rôle dans la tolérance à travers le transport de ces antigènes vers des organes centraux du système immunitaire. L'idée de la présente invention est d'exploiter cette réserve dans la préparation d'un certain nombre de produits. Ces produits comprennent les vaccins, les kits de laboratoire clinique et des composants de traitement. Les produits de vaccin couvrent : des vaccins contre des bactéries, des virus et des parasites chez les êtres humains et les animaux ; et des vaccins pour la prévention de tumeurs malignes chez des patients montrant une transformation maligne ou comme traitement de support chez des patients présentant déjà une tumeur. Les kits de laboratoire clinique couvrent : des kits de diagnostic pour un diagnostic efficace de maladies provoquées par des microorganismes chez des êtres humains et des animaux ; des kits de diagnostic pour des tumeurs malignes ; des kits de typage tissulaire pour la transplantation d'organes ; et des kits de suivi du rejet d'organes ou de l'hypersensibilité. Les composants de traitement aideront dans le traitement de troubles difficiles comprenant, entre autres, les troubles d'hypersensibilité, le rejet de greffe chronique et les troubles auto-immuns. En fait, les produits qui peuvent être préparés sur base de cette découverte sont indénombrables. Les procédés de l'invention sont basés sur la sélection d'antigènes transportés, spécifiques à une maladie, l'identification de ces antigènes, la production de ces antigènes puis la préparation d'un produit approprié.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EG2010/000041 WO2012059112A1 (fr) | 2010-11-01 | 2010-11-01 | Développement de produits médicaux fondés sur une fonction nouvellement découverte des érythrocytes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EG2010/000041 WO2012059112A1 (fr) | 2010-11-01 | 2010-11-01 | Développement de produits médicaux fondés sur une fonction nouvellement découverte des érythrocytes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012059112A1 true WO2012059112A1 (fr) | 2012-05-10 |
Family
ID=46024045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EG2010/000041 WO2012059112A1 (fr) | 2010-11-01 | 2010-11-01 | Développement de produits médicaux fondés sur une fonction nouvellement découverte des érythrocytes |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012059112A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018210395A1 (fr) | 2017-05-16 | 2018-11-22 | Mahmoud Abdel Wahed Rafea | Essai chromatographique en flux latéral pour la tuberculose (tb) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991016073A1 (fr) * | 1990-04-24 | 1991-10-31 | The University Of Newcastle Research Associates Limited | Vaccin oral comportant un antigene associe en surface a des erythrocytes |
| US20030045001A1 (en) * | 2001-08-29 | 2003-03-06 | Deborah Burgess | Immunochromatographic test strip with arcuate sample application zone for ease-of-use in the field |
| WO2009019317A1 (fr) * | 2007-08-08 | 2009-02-12 | Erytech Pharma | Composition et vaccin anti-tumoral thérapeutique |
| WO2009066131A1 (fr) * | 2007-11-19 | 2009-05-28 | Mahmoud Rafea | Procédés de préparation de vaccins, de nécessaires de laboratoire et de composants thérapeutiques |
-
2010
- 2010-11-01 WO PCT/EG2010/000041 patent/WO2012059112A1/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991016073A1 (fr) * | 1990-04-24 | 1991-10-31 | The University Of Newcastle Research Associates Limited | Vaccin oral comportant un antigene associe en surface a des erythrocytes |
| US20030045001A1 (en) * | 2001-08-29 | 2003-03-06 | Deborah Burgess | Immunochromatographic test strip with arcuate sample application zone for ease-of-use in the field |
| WO2009019317A1 (fr) * | 2007-08-08 | 2009-02-12 | Erytech Pharma | Composition et vaccin anti-tumoral thérapeutique |
| WO2009066131A1 (fr) * | 2007-11-19 | 2009-05-28 | Mahmoud Rafea | Procédés de préparation de vaccins, de nécessaires de laboratoire et de composants thérapeutiques |
Non-Patent Citations (1)
| Title |
|---|
| LUTZ, H. U.: "An age-specific cell antigen is present on senescent human red blood cell membranes.", MECHANISMS OF AGEING AND DEVELOPMENT, vol. 15, no. 1, 1981, pages 65 - 75 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018210395A1 (fr) | 2017-05-16 | 2018-11-22 | Mahmoud Abdel Wahed Rafea | Essai chromatographique en flux latéral pour la tuberculose (tb) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Immunology and immunodiagnosis of cystic echinococcosis: an update | |
| Ma et al. | Colorectal Cancer–Derived Foxp3+ IL‐17+ T Cells Suppress Tumour‐Specific CD8+ T Cells | |
| Gottstein et al. | Echinococcus metacestode: in search of viability markers | |
| Asito et al. | Alterations on peripheral B cell subsets following an acute uncomplicated clinical malaria infection in children | |
| Cannas et al. | Reduced cerebral infection of Neospora caninum–infected mice after vaccination with recombinant microneme protein NcMIC3 and ribi adjuvant | |
| Alaeddine et al. | Reduced infection and protection from clinical signs of cerebral neosporosis in C57BL/6 mice vaccinated with recombinant microneme antigen NcMIC1 | |
| Sirima et al. | Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa | |
| Cooper | General immunology | |
| Quillen et al. | Screening plateletpheresis donors for HLA antibodies on two high‐throughput platforms and correlation with recipient outcome | |
| Dinko et al. | Antibody responses to surface antigens of Plasmodium falciparum gametocyte‐infected erythrocytes and their relation to gametocytaemia | |
| Jafari et al. | Immunohistochemical observation of local inflammatory cell infiltration in the host-tissue reaction site of human hydatid cysts | |
| Rutkowski et al. | Alpha‐gal syndrome: An emerging cause of food and drug allergy | |
| Rowley et al. | Increase in macroglobin antibodies of mouse and pig following injection of bacterial lipopolysaccharide | |
| Haeney | Introduction to clinical immunology | |
| Sunita et al. | Immunodiagnosis of cystic echinocooccosis by antigen detection in serum, urine, and saliva samples | |
| Coovadia et al. | Alterations in immune responsiveness in acute measles and chronic post-measles chest disease | |
| Restrepo et al. | Analysis of the peripheral immune response in patients with neurocysticercosis: evidence for T cell reactivity to parasite glycoprotein and vesicular fluid antigens. | |
| Hsieh | A study of intracutaneous skin tests and radioallergosorbent tests on 1,000 asthmatic children in Taiwan | |
| Bussaratid et al. | Predictive factors for Gnathostoma seropositivity in patients visiting the gnathostomiasis clinic at the hospital for tropical diseases, Thailand during 2000-2005 | |
| Smael et al. | Association of Rhesus blood group (RhD) and toxoplasmosis in women with miscarriage in Erbil | |
| WO2012059112A1 (fr) | Développement de produits médicaux fondés sur une fonction nouvellement découverte des érythrocytes | |
| Soonawala et al. | The immune response to schistosome antigens in formerly infected travelers | |
| Zuckerman | Current status of the immunology of malaria and of the antigenic analysis of plasmodia: A five-year review | |
| Slavin et al. | Cell transfer of delayed hypersensitivity to ragweed from atopic subjects treated with emulsified ragweed extracts | |
| WO2009066131A1 (fr) | Procédés de préparation de vaccins, de nécessaires de laboratoire et de composants thérapeutiques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10859196 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 10859196 Country of ref document: EP Kind code of ref document: A1 |